Details of the Drug

General Information of Drug (ID: DMLW57T)

Drug Name
Teniposide
Synonyms
PTG; Teniposido; Teniposidum; Vehem; Vumon; Demethyl Epipodophyllotoxin Thenylidine Glucoside; VM 26; Teniposido [INN-Spanish]; Teniposidum [INN-Latin]; VM-26; Vee M-26; Veham-Sandoz; Vumon (TN); Teniposide (USAN/INN); Teniposide [USAN:BAN:INN]; VM-26 (TN); Vumon, VM-26, Vehem, NSC 122819, Teniposide; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin thenylidene glucoside; 4'-Demethylepipodophyllotoxin-beta-D-thenylidine glucoside; 4'-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin; 4-Demethylepipodophyllotoxin-.beta.-D-thenylideneglucoside
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [1]
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01CB02: Teniposide
L01CB: Podophyllotoxin derivatives
L01C: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 656.7
Logarithm of the Partition Coefficient (xlogp) 1.2
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 14
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.19 mL/min/kg [3]
Elimination
9% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 hours [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 10.65988 micromolar/kg/day [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.0044% [3]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.41 L/kg [3]
Water Solubility
The ability of drug to dissolve in water is measured as 0.025 mg/mL [2]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Cytogenetic abnormality Not Available G6PD OT300SMK [5]
Cytogenetic abnormality Not Available TOP2A OT6LPS08 [5]
Cytogenetic investigations Not Available TOP1 OT51O0CF [5]
Chemical Identifiers
Formula
C32H32O13S
IUPAC Name
(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one
Canonical SMILES
COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O
InChI
InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1
InChIKey
NRUKOCRGYNPUPR-QBPJDGROSA-N
Cross-matching ID
PubChem CID
452548
CAS Number
29767-20-2
UNII
957E6438QA
DrugBank ID
DB00444
TTD ID
D01DBQ
VARIDT ID
DR00021
INTEDE ID
DR1550

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN ; TOP2B_HUMAN Modulator [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 3 (ABCC3) DTQ3ZHF MRP3_HUMAN Substrate [7]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [8]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [9]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cholesteryl ester transfer protein (CETP) OTAGPPOE CETP_HUMAN Gene/Protein Processing [12]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Gene/Protein Processing [12]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Biotransformations [11]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Biotransformations [11]
DNA topoisomerase 1 (TOP1) OT51O0CF TOP1_HUMAN Drug Response [5]
DNA topoisomerase 2-alpha (TOP2A) OT6LPS08 TOP2A_HUMAN Drug Response [5]
Fibroblast growth factor 2 (FGF2) OT7YUJ9F FGF2_HUMAN Drug Response [13]
Glucose-6-phosphate 1-dehydrogenase (G6PD) OT300SMK G6PD_HUMAN Drug Response [5]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Gene/Protein Processing [14]
Nuclear receptor-interacting protein 1 (NRIP1) OTIZOJQV NRIP1_HUMAN Gene/Protein Processing [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC2 2.0251 6.0377 -0.2861 10.5659
ES8 GDSC2 -4.2159 -1.5578 -4.2358 57.9301
ES7 GDSC2 -4.0213 -0.5025 -4.1152 55.714
SK-PN-DW GDSC2 -4.0212 -2.7095 -4.0213 56.2552
EW-3 GDSC2 -3.8465 0.5529 -4.0961 53.81
SK-ES-1 GDSC2 -3.8312 1.0966 -4.2 53.4962
EW-22 GDSC2 -3.3158 -0.8497 -3.344 49.199
HuO9 GDSC2 -2.6585 -0.1111 -2.7166 42.7953
EW-16 GDSC2 -2.6584 0.9711 -2.8939 43.2954
A-673 GDSC2 -2.6539 0.3719 -2.7752 42.9447
MHH-ES-1 GDSC2; CTRP2 -2.5615 -0.0359 -2.5645 50.6693
TC-71 GDSC2 -2.3777 0.8298 -2.5593 40.467
EW-13 GDSC2 -2.1784 3.0497 -2.9981 40.5305
HOS GDSC2 -1.4668 2.3924 -1.9964 33.141
EW-11 GDSC2 -1.3425 2.6178 -1.9414 32.27
EW-1 GDSC2 -1.3071 2.2123 -1.7624 31.2754
EW-7 GDSC2 -1.2661 5.3282 -2.9856 35.7673
ES5 GDSC2 -0.5929 10.8804 -4.9827 37.7423
EW-24 GDSC2 -0.4941 4.8635 -1.9975 28.6064
SaOS-2 GDSC2 -0.418 3.0186 -1.1092 23.8521
NY GDSC2 -0.2916 4.8811 -1.8042 26.8708
CAL-72 GDSC2 -0.2263 2.5077 -0.7027 20.7761
CADO-ES1 GDSC2 -0.1855 4.2467 -1.4061 24.4585
MG-63 GDSC2 0.4732 2.6675 -0.0311 14.0015
U2OS GDSC2; CTRP2; CTRP1 0.6813 3.4975 0.5988 29.3447
H-EMC-SS GDSC2 0.8157 8.1955 -2.3814 25.3295
HuO-3N1 GDSC2 1.0512 4.6301 -0.4025 14.177
EW-18 GDSC2 1.5896 4.3881 0.1872 8.8313
ES6 GDSC2 1.8848 5.2463 -0.0022 9.1919
SW1353 CTRP2 2.1273 6.672 1.3051 22.4037
ES4 GDSC2 2.1532 6.5349 -0.4339 11.121
CAL-78 GDSC2; CTRP2 2.2579 7.4076 1.143 22.6308
NOS-1 [Human HNSCC] GDSC2 2.5009 6.2374 -0.0292 7.8164
CHSA8926 GDSC2 2.5471 6.4047 -0.0777 8.003
SJSA-1 CTRP2 3.1736 8.8157 1.4387 19.0983
G-292 clone A141B1 GDSC2 3.8268 6.4063 0.6874 1.627
⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 173 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JK1 CTRP2 -6.9288 -0.8173 -7.0029 74.6536
TALL-1 [Human adult T-ALL] CTRP2 -8.7067 6.468 -10.3742 69.6118
MOLT-16 GDSC2; CTRP2 -8.4208 -7.3792 -8.4208 89.5882
SU-DHL-8 GDSC2; CTRP2 -7.9062 -5.7341 -7.9062 85.5061
RCH-ACV CTRP2 -7.6874 -3.9714 -7.6893 82.2236
Reh GDSC2; CTRP2 -7.5301 -6.6408 -7.5301 83.7664
NU-DUL-1 CTRP2; CTRP1 -7.4411 -2.5843 -7.4566 79.1533
BV-173 CTRP2 -7.3691 -6.4707 -7.3691 82.6957
NB4 CTRP2 -7.3675 -6.9468 -7.3675 82.6899
MV4-11 CTRP2 -7.0247 -4.6086 -7.0247 79.9177
KMS-34 CTRP2 -6.7666 -4.2127 -6.7666 78.2079
DoHH2 GDSC2; CTRP2 -6.749 -5.0577 -6.749 78.4915
SU-DHL-5 GDSC2; CTRP1 -6.693 -5.6788 -6.693 83.7258
MHH-CALL-4 CTRP2 -6.4618 -0.3536 -6.549 72.3257
SR GDSC2; CTRP2 -6.3844 -4.9361 -6.3844 76.1209
RPMI-8402 CTRP2 -6.2908 -3.8254 -6.2909 75.2396
SKM-1 GDSC2; CTRP2; CTRP1 -5.9637 -3.452 -5.9638 73.1117
MOLM-13 GDSC2; CTRP2 -5.89 -2.6678 -5.8917 72.2638
CML-T1 GDSC2; CTRP2 -5.8317 -4.0895 -5.8317 72.4294
WIL2 NS GDSC2 -5.6061 -3.79 -5.6064 71.8801
HPB-ALL CTRP2 -5.5023 -0.3676 -5.5529 68.2832
SU-DHL-4 CTRP2; CTRP1 -5.3965 1.1084 -5.5657 66.3114
P12-Ichikawa GDSC2; CTRP2 -5.3752 -3.197 -5.3752 69.3529
JVM-3 GDSC2; CTRP2 -5.3099 -1.8569 -5.3142 68.4686
KE-37 GDSC2; CTRP2 -5.1749 -3.1642 -5.1749 68.0498
RS4;11 GDSC2; CTRP2 -5.1683 -2.5553 -5.1688 67.9012
EoL-1 GDSC2 -5.1052 -3.557 -5.1053 67.0698
IM-9 GDSC2 -5.063 -3.3608 -5.0633 66.6076
SUP-M2 GDSC2 -4.9909 -3.6071 -4.9909 65.9602
EB2 GDSC2 -4.9888 -2.0147 -5.0097 65.0079
WSU-NHL GDSC2 -4.9824 -1.2614 -5.0511 64.1077
KE-97 CTRP2 -4.966 -1.7772 -4.9689 66.3968
THP-1 CTRP2; CTRP1 -4.9609 -0.6884 -4.9834 65.7803
SCC-3 GDSC2 -4.8869 -2.5591 -4.8916 64.5834
A3/Kawakami GDSC2 -4.8859 -2.4119 -4.8931 64.4757
SUP-B15 GDSC2 -4.8152 -3.0699 -4.8157 64.1395
MOLM-6 CTRP2 -4.814 2.8132 -5.1977 62.266
CESS GDSC2 -4.7483 -1.5509 -4.7854 62.5854
Raji GDSC2; CTRP2 -4.6844 1.0453 -4.8065 63.0729
Ri-1 CTRP2 -4.6465 0.4815 -4.7188 63.2893
KOPN-8 GDSC2 -4.6302 -2.9868 -4.6305 62.3215
CCRF-CEM GDSC2 -4.5834 -1.0536 -4.651 60.7931
SUP-T1 GDSC2; CTRP2 -4.5115 3.7843 -5.0691 60.2627
JVM-2 GDSC2; CTRP2 -4.4739 0.166 -4.52 62.5593
MC116 CTRP2 -4.4621 -1.338 -4.4656 63.1501
MOLT-13 GDSC2; CTRP2 -4.4438 0.3135 -4.4972 62.3067
OCI-AML-2 GDSC2; CTRP2 -4.402 -2.2392 -4.4022 62.911
NALM-6 GDSC2; CTRP2 -4.3502 -1.8262 -4.3508 62.5328
ATN-1 GDSC2 -4.3115 -3.3416 -4.3115 59.1714
WSU-DLCL2 CTRP2; CTRP1 -4.2175 -1.918 -4.2178 61.6762
Namalwa GDSC2 -4.1792 -2.0994 -4.1835 57.7541
CTV-1 GDSC2 -4.1517 -2.0734 -4.1561 57.4822
H9 GDSC2 -4.1432 -0.6331 -4.2294 56.8288
SU-DHL-10 GDSC2; CTRP2 -4.1245 -0.0395 -4.1511 60.6497
BL-41 GDSC2 -4.1189 -1.4712 -4.1399 56.9973
HC-1 GDSC2 -4.108 -1.7351 -4.119 56.9794
ML-2 GDSC2 -4.0622 0.6113 -4.3421 55.4864
BC-1 GDSC2 -4.0538 -0.7365 -4.1242 56.1039
L-428 GDSC2 -4.018 -0.3463 -4.131 55.6134
A4/Fukuda GDSC2 -3.9338 -0.6216 -4.0094 54.9934
L-540 GDSC2; CTRP2 -3.9174 -2.0656 -3.9174 59.7005
697 GDSC2 -3.9046 -1.3876 -3.9234 54.954
Daudi GDSC2 -3.8797 0.1058 -4.0498 54.2498
SU-DHL-1 CTRP2 -3.8653 -2.2452 -3.8653 59.3567
PF-382 GDSC2; CTRP2 -3.862 -0.7657 -3.867 59.2297
MM1.S GDSC2; CTRP2 -3.775 -1.5066 -3.7754 58.7403
DEL GDSC2; CTRP2 -3.761 -2.159 -3.7611 58.6622
U-937 CTRP2; CTRP1 -3.7329 -1.7693 -3.733 58.4705
MHH-CALL-3 CTRP2 -3.7132 19.647 -10.4111 52.8259
OCI-AML-3 GDSC2; CTRP1 -3.6348 0.3941 -3.7922 54.0398
ALL-SIL GDSC2; CTRP2 -3.6071 -0.5596 -3.6125 57.5618
VAL GDSC2 -3.6058 1.1426 -3.9655 51.7107
BALL-1 GDSC2 -3.5913 -1.5993 -3.5972 51.9278
EM-2 GDSC2; CTRP2 -3.579 -1.5542 -3.5792 57.4451
SU-DHL-6 GDSC2; CTRP2 -3.5452 0.7067 -3.5904 56.9177
P31/FUJ CTRP2 -3.506 -0.579 -3.5104 56.9095
MLMA GDSC2 -3.4951 0.2193 -3.6548 50.8813
JSC-1 GDSC2 -3.4344 0.3051 -3.604 50.3327
MHH-CALL-2 GDSC2 -3.3599 -1.2682 -3.3704 49.6261
KMS-21-BM CTRP2 -3.3551 -0.4116 -3.3601 55.9113
KMS-26 CTRP2 -3.3456 -1.6531 -3.3456 55.8943
LC4-1 GDSC2 -3.2501 0.5888 -3.4569 48.682
Mono-Mac-1 CTRP2 -3.244 0.8003 -3.2843 55.0393
Karpas-231 GDSC2 -3.2162 -1.5885 -3.2184 48.1843
KMS-27 CTRP2 -3.2142 -2.5157 -3.2142 55.0197
KMS-12-BM GDSC2; CTRP2 -3.2087 0.8222 -3.249 54.8148
NCO2 CTRP2 -3.2002 -0.2922 -3.2054 54.891
P30/OHK GDSC2 -3.1738 -1.1571 -3.1841 47.7748
RPMI-6666 GDSC2 -3.1395 0.6299 -3.3451 47.6803
ARH-77 GDSC2 -3.1351 -0.7041 -3.1657 47.4242
MOLM-16 CTRP2; CTRP1 -3.1285 2.2551 -3.297 54.0473
GA-10 GDSC2 -3.0671 1.6946 -3.5223 47.2906
Peer CTRP2 -3.0581 0.7258 -3.089 53.8777
KMS-28BM CTRP2 -3.0442 2.3294 -3.2171 53.5394
ALL-PO GDSC2 -3.0019 1.783 -3.4762 46.7637
KHM-1B CTRP2 -2.9925 -1.7011 -2.9925 53.5428
SUP-T11 CTRP2 -2.9598 2.6952 -3.1798 52.9819
DND-41 GDSC2 -2.9437 -0.0204 -3.0293 45.6598
Ki-JK CTRP2 -2.8564 2.0367 -2.981 52.4599
KYO-1 CTRP2 -2.836 -0.6991 -2.8366 52.4983
Hs 445 GDSC2 -2.6379 4.2813 -3.963 44.9896
Jurkat GDSC2; CTRP2 -2.6286 -1.253 -2.6286 51.1189
TUR GDSC2 -2.5092 0.0854 -2.5807 41.3678
SUP-HD1 GDSC2 -2.4857 1.6372 -2.8719 42.0901
Jiyoye GDSC2 -2.4713 2.9286 -3.2698 42.9026
GDM-1 GDSC2; CTRP1 -2.4695 1.4849 -2.739 44.0847
VL51 GDSC2 -2.4588 1.2432 -2.7397 41.5522
JURL-MK1 GDSC2; CTRP2 -2.438 -0.2288 -2.4392 49.8492
L-363 GDSC2; CTRP2 -2.4112 1.6047 -2.4721 49.6811
EHEB CTRP2 -2.4015 3.3326 -2.6863 49.6477
KM-H2 GDSC2; CTRP2 -2.3687 1.1348 -2.3989 49.398
ST486 GDSC2 -2.3059 1.5474 -2.6511 40.3196
PL21 CTRP1 -2.2505 0.1835 -2.2948 60.546
RPMI-8226 GDSC2; CTRP1 -2.211 1.6041 -2.4851 41.7988
HL-60 GDSC2 -2.1739 -0.1885 -2.2017 37.8519
P32/ISH GDSC2 -2.0603 1.2311 -2.3024 37.6248
KY821 GDSC2 -1.9645 0.3056 -2.029 35.9268
Karpas-299 GDSC2 -1.8592 2.5018 -2.4588 37.0656
RPMI-8866 GDSC2 -1.8428 1.7935 -2.2149 36.0529
OCI-M1 GDSC2 -1.8073 0.9931 -1.9739 34.8318
HEL GDSC2; CTRP2 -1.7358 0.5142 -1.7385 45.1777
NOMO-1 GDSC2; CTRP1 -1.6725 -0.2375 -1.6768 35.7649
HAL-01 GDSC2 -1.5954 1.0108 -1.7476 32.6643
Granta-519 GDSC2 -1.5928 3.4484 -2.5241 35.8676
DB GDSC2 -1.5276 5.3083 -3.2426 37.7383
NCI-H929 GDSC2; CTRP2 -1.5271 1.9648 -1.5771 43.8959
RC-K8 GDSC2 -1.4995 4.9805 -3.0692 37.1247
Farage GDSC2 -1.3595 6.626 -3.6723 38.033
MEG-01 GDSC2 -1.3315 4.0217 -2.4829 34.402
BE-13 GDSC2 -1.2524 0.9793 -1.3696 29.0691
Karpas-422 GDSC2 -1.2494 1.6818 -1.5352 29.8901
HT CTRP2 -1.1792 2.1842 -1.2308 41.6033
AMO1 GDSC2; CTRP2; CTRP1 -1.1453 2.234 -1.1994 41.3854
Loucy GDSC2 -1.0537 2.1669 -1.4723 28.63
KMS-11 CTRP2; CTRP1 -0.9555 2.5933 -1.0324 40.1909
Ku812 GDSC2; CTRP2 -0.9262 3.0965 -1.0615 40.149
LAMA-84 GDSC2; CTRP2 -0.9133 2.0163 -0.9436 39.7824
Kasumi-1 GDSC2 -0.7803 8.1975 -3.8526 36.0503
EJM GDSC2; CTRP1 -0.7717 1.2379 -0.851 27.5018
MOLT-4 GDSC2 -0.7021 2.555 -1.2298 25.7493
OCI-AML-5 GDSC2 -0.5708 3.9429 -1.6612 27.3669
KMS-18 CTRP2 -0.5671 3.5615 -0.7478 37.9173
OPM-2 GDSC2 -0.5291 3.4201 -1.3927 25.8366
SK-MM-2 GDSC2; CTRP2 -0.4258 6.538 -1.391 38.8863
MOLP-8 GDSC2 -0.4137 6.406 -2.6424 30.9006
HDLM-2 GDSC2; CTRP2 -0.4119 2.8118 -0.4815 36.5706
TK [Human B-cell lymphoma] GDSC2 -0.2773 1.3477 -0.3878 19.2632
MN-60 GDSC2 -0.2536 6.3133 -2.444 29.496
KCL-22 GDSC2; CTRP2 -0.2138 3.0838 -0.3015 35.3122
U-698-M GDSC2 0.0936 3.3618 -0.725 19.5816
DG-75 GDSC2 0.2119 5.468 -1.593 23.8517
MHH-PREB-1 GDSC2 0.2475 2.3431 -0.1342 15.5261
Karpas-1106P GDSC2 0.2477 6.7584 -2.1862 26.4971
Ramos.2G6.4C10 GDSC2 0.2964 1.5432 0.1899 13.4906
BL-70 CTRP1 0.3137 5.2442 -2.3245 19.1573
KMOE-2 GDSC2 0.3489 2.1925 0.0323 14.141
U266B1 GDSC2 0.3597 5.6184 -1.5259 22.9591
KG-1 GDSC2 0.3997 2.728 -0.1332 14.8984
GR-ST GDSC2 0.4524 6.38 -1.8114 24.0342
K-562 GDSC2 0.5296 3.45 -0.3263 15.5487
CA46 GDSC2 0.7134 6.5103 -1.6371 22.2541
JJN-3 GDSC2 1.1781 3.3114 0.363 9.0064
Karpas-45 GDSC2 1.6861 5.0445 -0.0612 10.1112
ME1 GDSC2 1.9675 11.9942 -3.3044 25.3499
P3HR-1 CTRP2 3.1789 14.3839 -1.2585 27.8411
Mono-Mac-6 CTRP2 3.232 14.9839 -1.5062 28.3446
LP-1 GDSC2; CTRP1 3.2623 6.4233 0.7797 4.9561
OCI-Ly10 CTRP1 3.445 9.4604 -0.5599 16.6622
HH [Human lymphoma] GDSC2 4.1034 6.3949 0.8165 0.8958
L-1236 GDSC2; CTRP2 4.27 15.7974 -0.9904 24.6577
Karpas-620 GDSC2; CTRP2 4.9776 6.2217 4.3992 2.8439
KMM-1 CTRP2 8.0744 10.4314 4.2695 0.4119
REC-1 CTRP2 8.1582 10.0061 4.4511 0.1365
⏷ Show the Full List of 173 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE8 CTRP2 0.113 4.7089 -0.2496 34.0017
KYSE-510 GDSC2 -1.8432 3.1781 -2.6863 37.7438
TE-15 GDSC2 -0.911 2.1049 -1.2968 27.0593
EC-GI-10 GDSC2 -0.6093 3.1165 -1.3506 25.9694
KYSE-270 GDSC2 -0.4907 2.5853 -1.0148 23.6537
OE33 GDSC2 -0.4254 3.7697 -1.4361 25.614
TE-8 GDSC2 -0.1513 4.0723 -1.2923 23.7212
TE-9 GDSC2; CTRP2 0.574 3.4542 0.4902 30.063
TE-5 GDSC2 1.1637 5.2095 -0.5893 14.9386
TE-1 GDSC2; CTRP2 1.2374 3.3216 1.2037 25.4761
TE-4 GDSC2; CTRP2 1.271 4.5313 1.0543 25.882
KYSE-180 GDSC2; CTRP2 1.2868 2.3743 1.2863 25.0352
TE-6 GDSC2; CTRP2 1.7237 4.1058 1.6268 22.4526
COLO 680N GDSC2; CTRP2 2.5966 8.177 1.1567 21.6553
KYSE-140 GDSC2; CTRP2 2.6324 5.4178 2.3015 17.2427
TE-10 CTRP2 2.905 6.2379 2.302 16.4578
KYSE-520 GDSC2 3.0744 10.2104 -1.5582 15.0227
KYSE-70 GDSC2; CTRP2 3.3408 7.7299 2.1093 16.0573
OE19 GDSC2 3.4907 8.8511 -0.609 9.041
OE21 GDSC2 3.6625 5.5375 0.9569 0.7194
KYSE-450 GDSC2 4.2048 15.6076 -3.381 20.1794
KYSE-410 GDSC2 5.4658 16.8565 -3.109 16.669
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
FLO-1 GDSC2 -1.7526 2.4489 -2.3252 35.99
KYSE-220 GDSC2 -1.6282 1.9245 -2.02 34.0817
OACM5.1 C GDSC2 -1.4071 2.2053 -1.8687 32.2679
ESO-26 GDSC2 1.1307 3.834 0.0626 11.041
TE-12 GDSC2 1.3808 9.5195 -2.5537 24.2292
ESO-51 GDSC2 1.5192 3.6223 0.511 6.9932
KYSE-50 GDSC2 1.7598 5.0951 -0.0266 9.6877
OACP4 C GDSC2 1.8348 5.5564 -0.1966 10.5335
KYAE-1 GDSC2 1.9418 4.8935 0.2179 7.6659
SK-GT-4 GDSC2 2.6814 11.6127 -2.5471 20.5437
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC2 2.2181 5.9346 -0.0874 8.8521
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MHH-NB-11 CTRP2 -5.4805 -1.467 -5.492 69.1548
IMR-5 GDSC2 -4.0551 -1.9395 -4.0606 56.5189
SJNB-13 GDSC2 -3.6802 1.0138 -4.0158 52.3337
CHP-134 GDSC2 -3.6783 1.3586 -4.0988 52.241
NB69 GDSC2 -3.4087 1.4611 -3.8314 50.0901
CHP-126 CTRP2 -3.223 0.3038 -3.2415 54.9816
Kelly GDSC2 -2.8677 0.6275 -3.0504 45.1348
NB1 CTRP2 -2.5764 2.0068 -2.6817 50.7297
SJNB-10 GDSC2 -2.3543 1.8455 -2.788 41.0274
SiMa GDSC2; CTRP2 -1.8376 1.3074 -1.8608 45.8941
NH-12 GDSC2 -1.667 3.2121 -2.511 36.2101
SJNB-14 GDSC2 -1.6347 3.6838 -2.6623 36.5564
KP-N-SI9s CTRP2 -1.6043 4.733 -2.1289 45.091
CHP-212 GDSC2 -1.5145 5.3451 -3.2456 37.6836
SK-N-DZ GDSC2 -0.3977 4.732 -1.8408 27.4837
KP-N-YN GDSC2 0.4518 8.9472 -3.0784 29.2314
SK-N-BE(2)-M17 GDSC2 0.5676 4.7831 -0.9248 18.9377
SK-N-AS GDSC2 0.6058 5.7922 -1.3816 21.3174
GOTO GDSC2 0.7319 9.1397 -2.9249 27.74
NB(TU)1 GDSC2 0.7913 5.7318 -1.1821 19.5933
TGW GDSC2 0.9613 6.6266 -1.4728 20.571
SJNB-7 GDSC2 1.8001 5.4559 -0.1743 10.492
GI-ME-N GDSC2 2.6817 7.568 -0.549 10.4835
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-478 CTRP2 -1.9479 1.8674 -2.0088 46.6746
SNU-1196 CTRP2 0.6652 6.0071 -0.0285 31.447
SNU-1079 CTRP2 0.6756 6.2102 -0.086 31.5897
HuCC-T1 GDSC2; CTRP2 1.4221 4.5962 1.204 24.8824
HuH-28 CTRP2 3.1749 6.095 2.645 14.3944
SNU-308 CTRP2 4.5006 7.743 3.2188 8.7916
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 47 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DU4475 GDSC2 -4.5837 -0.5267 -4.71 60.3165
CAL-148 CTRP2 -2.9508 1.6654 -3.0423 53.0854
CAL-51 GDSC2; CTRP2 -1.5186 3.5314 -1.7688 44.1966
AU565 GDSC2 -0.8368 2.3659 -1.306 26.763
MDA-MB-157 GDSC2 -0.7952 1.8158 -1.0791 25.3743
HCC1569 GDSC2 -0.3236 3.6943 -1.2985 24.466
HMC-1-8 CTRP2 -0.2105 3.0495 -0.294 35.2772
MDA-MB-468 GDSC2 -0.1741 6.8139 -2.609 29.8225
OCUB-M GDSC2 -0.0832 3.7335 -1.0706 22.2434
Hs 578T GDSC2 0.1682 2.4858 -0.2748 16.6687
MDA-MB-231 GDSC2 0.1913 2.8544 -0.4034 17.3216
HCC1954 GDSC2; CTRP2 0.4316 2.1891 0.4266 30.748
CAL-85-1 GDSC2 0.8604 5.9785 -1.2415 19.6813
HCC1806 GDSC2; CTRP2 0.8984 4.2433 0.7105 28.2583
HCC2157 GDSC2 1.42 3.883 0.2957 8.6539
HCC38 GDSC2 1.4637 5.0701 -0.2597 11.9958
EFM-19 GDSC2 1.49 5.451 -0.4277 12.9464
CAL-120 GDSC2; CTRP2 1.4972 5.3254 1.093 25.0403
HDQ-P1 GDSC2; CTRP2 1.6125 4.6422 1.4007 23.5944
MRK-nu-1 GDSC2 1.6201 6.2556 -0.7211 14.3147
JIMT-1 GDSC2; CTRP2 1.6637 2.3332 1.6637 22.5229
BT-549 GDSC2 1.733 7.9966 -1.4983 18.2836
T-47D GDSC2 1.7673 6.3694 -0.657 13.509
MFM-223 GDSC2 1.8272 4.7122 0.2184 7.968
BT-20 GDSC2 1.9901 4.3333 0.5321 5.576
MDA-MB-436 GDSC2 2.0049 9.582 -2.0692 20.281
HCC1187 GDSC2 2.0753 3.9671 0.7737 3.8743
COLO 824 GDSC2 2.4078 6.6123 -0.2802 9.5535
EFM-192A GDSC2 2.4265 7.3179 -0.614 11.4855
MDA-MB-453 GDSC2 2.4502 13.5795 -3.7073 25.4123
ZR-75-30 GDSC2 2.6477 5.4745 0.4386 4.6851
HCC1143 GDSC2; CTRP2 2.6582 5.1419 2.413 16.7582
HCC1500 GDSC2 2.6682 6.2513 0.0812 6.7757
ZR-75-1 CTRP2 2.6768 9.1412 0.7971 22.7535
MDA-MB-330 GDSC2 2.6784 8.7595 -1.1368 13.7969
HCC1395 CTRP2 2.8067 8.6827 1.1382 21.1693
HCC1428 GDSC2 2.8793 4.5422 0.9949 1.2624
HCC70 GDSC2 3.1743 7.4114 -0.134 6.989
BT-474 GDSC2 3.361 4.7868 1.1145 0.4086
HCC1419 GDSC2 3.5155 5.4768 0.9163 0.9751
HCC1937 GDSC2; CTRP2 3.6108 7.0296 2.6997 13.0221
MDA-MB-361 GDSC2 3.6822 11.2474 -1.6297 13.9798
Evsa-T GDSC2 3.7887 9.8649 -0.8939 9.9867
MDA-MB-415 GDSC2 3.8335 12.3617 -2.064 15.6878
MCF-7 GDSC2; CTRP2; CTRP1 4.0096 12.6298 0.3582 21.0593
CAMA-1 GDSC2; CTRP2 4.526 11.9739 1.1387 17.1339
KPL-1 CTRP2 5.0778 9.9933 2.5977 10.2019
⏷ Show the Full List of 47 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 0.4409 3.4747 0.3458 30.9865
Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
H4 GDSC2 -3.0652 3.2638 -4.0304 47.6711
D283 Med GDSC2 -2.4464 1.5028 -2.7924 41.6218
Daoy GDSC2; CTRP2 -1.7099 1.5507 -1.7409 45.0638
8-MG-BA GDSC2 -1.2143 3.5788 -2.1763 32.6408
SF539 GDSC2 -1.0831 3.8633 -2.1571 31.9334
M059J GDSC2 -1.0313 2.2047 -1.4607 28.4649
U-251MG GDSC2 -0.4826 4.7358 -1.9275 28.2418
AM-38 GDSC2 -0.4397 3.3289 -1.2611 24.761
LN-18 GDSC2; CTRP2 -0.1106 2.2058 -0.1263 34.3951
GI-1 GDSC2 -0.0198 2.5854 -0.5137 18.8281
YH-13 GDSC2 0.0664 5.2411 -1.6236 24.5628
SK-MG-1 GDSC2 0.1497 2.7935 -0.4209 17.5924
SF126 CTRP2 0.1968 3.9468 0.0083 32.9111
SF268 GDSC2 0.2715 3.6195 -0.6614 18.515
SF295 CTRP2 0.3828 6.4453 -0.4843 33.7435
KS-1 [Human Krukenberg tumour] GDSC2 0.4427 6.2436 -1.7535 23.7896
42-MG-BA GDSC2 0.5786 4.4844 -0.77 18.0045
U-118MG GDSC2 0.7426 3.8784 -0.322 14.7446
SNU-626 CTRP2 0.7637 4.1879 0.5756 29.1533
T98G GDSC2 0.9964 2.9792 0.3523 9.7027
KALS-1 GDSC2; CTRP2 1.053 4.9462 0.7149 27.7475
SW1088 GDSC2; CTRP2 1.0592 5.9849 0.4063 28.7738
PFSK-1 GDSC2 1.1645 6.5719 -1.267 18.8123
D-263MG GDSC2 1.2056 4.5791 -0.2389 12.6703
KNS-60 CTRP2 1.2292 4.5199 1.0114 26.1636
Becker GDSC2 1.2618 6.9628 -1.3777 19.0934
ONS-76 GDSC2; CTRP2 1.4151 4.9497 1.1091 25.2376
GB-1 GDSC2; CTRP2 1.5364 5.4345 1.1028 24.885
SNU-466 CTRP2 1.8481 6.621 1.0272 24.2229
LN-229 GDSC2; CTRP2; CTRP1 1.8733 6.315 1.1693 23.6361
DK-MG GDSC2 1.9157 4.236 0.524 5.8146
SNU-738 CTRP2 2.131 4.6368 1.9662 19.9782
GaMG GDSC2; CTRP2; CTRP1 2.1389 7.2414 1.0879 23.1666
CAS-1 GDSC2; CTRP2 2.3815 6.3564 1.6982 20.2174
A-172 GDSC2 2.4537 9.8017 -1.8237 17.8951
LN-405 GDSC2 3.0386 9.2973 -1.1371 12.9257
SNU-489 CTRP2 3.6978 7.605 2.5213 13.5213
U-87MG ATCC GDSC2; CTRP2 3.8097 9.4904 1.7239 16.4552
D-392MG GDSC2 4.0073 6.8779 0.5809 1.9061
SNU-1105 CTRP2 4.0532 7.9743 2.6891 11.9908
DBTRG-05MG GDSC2; CTRP2 4.2039 12.7865 0.4524 20.3051
SNU-201 CTRP2 4.7535 13.7207 0.4615 19.1043
KINGS-1 GDSC2 4.9559 17.3198 -3.681 19.6764
KNS-81 CTRP2 4.9856 11.2086 1.9132 13.1793
NMC-G1 CTRP2 5.8357 11.1392 2.6287 8.7022
⏷ Show the Full List of 45 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ETK-1 GDSC2 2.0232 5.8822 -0.2103 10.1074
TGBC24TKB GDSC2 3.5539 6.4936 0.5122 2.7725
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHUEM-2 CTRP2; CTRP1 -5.0753 -0.9024 -5.0936 66.5513
ESS-1 GDSC2 -3.5545 -1.7788 -3.5573 51.5684
RL95-2 GDSC2; CTRP2 -0.4922 2.8794 -0.5732 37.1377
MFE-280 GDSC2 -0.426 2.4496 -0.8944 22.7095
HEC-151 CTRP2; CTRP1 0.1463 2.7958 0.1055 32.7668
MFE-319 GDSC2 0.3763 2.2246 0.0492 13.9286
HEC-265 CTRP2 0.3922 1.7265 0.3916 30.9957
HEC-6 CTRP2 0.4103 3.1489 0.3511 31.0705
KLE GDSC2; CTRP2; CTRP1 0.4678 5.3478 -0.0362 32.1294
HEC-59 CTRP2; CTRP1 0.8759 1.7751 0.8759 27.7711
HEC-251 CTRP2 0.9128 3.677 0.8219 27.8321
HEC-1-B CTRP2 1.4896 2.2917 1.4896 23.6824
AN3-CA GDSC2 1.616 3.4569 0.6748 5.673
EN GDSC2 1.6254 3.0969 0.8624 4.4589
MFE-296 GDSC2 1.6919 5.2688 -0.1686 10.7622
HEC-50B CTRP2 1.9864 4.3164 1.874 20.7568
EFE-184 CTRP2 4.3203 6.5838 3.6112 7.5847
HEC-108 CTRP2; CTRP1 4.9021 10.1644 2.3649 11.5084
Ishikawa (Heraklio) 02 ER- CTRP2; CTRP1 1.2713 1.9428 1.2713 25.1369
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ACHN GDSC2 -2.1349 3.4072 -3.0854 40.5014
SW13 GDSC2 -0.8531 2.9582 -1.5454 28.0584
786-O GDSC2 -0.5605 5.3414 -2.2843 30.1156
LB996-RCC GDSC2 -0.0213 7.8987 -2.9935 30.6285
CAL-54 GDSC2 0.0044 7.7831 -2.9131 30.2539
TK-10 GDSC2 0.5959 5.2381 -1.1196 19.9332
BFTC-909 GDSC2; CTRP2 0.6214 4.0093 0.4555 30.0234
KTCTL-195 GDSC2 0.7601 6.7689 -1.7229 22.5186
RXF 393L GDSC2 1.4618 6.9242 -1.188 17.4463
SN12C GDSC2 1.52 5.1743 -0.2641 11.8544
HA7-RCC GDSC2 1.9794 7.1577 -0.8799 14.2071
KMRC-20 GDSC2; CTRP2 2.0468 5.7391 1.56 21.7001
NCC010 GDSC2 2.1369 5.6185 0.0076 8.472
TUHR4TKB CTRP2 2.2727 5.4034 1.9144 19.7322
RCC10RGB GDSC2; CTRP1 2.7022 4.8969 1.1337 4.0386
VMRC-RCW CTRP2 2.885 5.0093 2.6973 15.0418
769-P GDSC2; CTRP2 3.052 6.9248 2.1738 16.5522
A-498 GDSC2 3.1274 4.4215 1.1557 0.4157
A-704 GDSC2 3.9056 5.6571 1.0111 0.4237
VMRC-RCZ GDSC2 3.9092 6.2698 0.7802 1.173
OS-RC-2 GDSC2; CTRP2 4.1367 7.571 2.963 10.6729
SNU-1272 CTRP2 4.1664 8.4018 2.5876 12.148
TUHR10TKB CTRP2 5.2014 8.0396 3.6756 5.4575
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 56 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CL-34 CTRP2; CTRP1 -4.5215 3.0085 -4.918 60.8459
SW48 GDSC2; CTRP2 -3.7125 0.6203 -3.7584 57.9536
SNU-175 GDSC2; CTRP2; CTRP1 -2.6604 2.8721 -2.8862 51.2021
LoVo GDSC2; CTRP2; CTRP1 -1.9602 5.1322 -2.6241 47.2615
SK-CO-1 GDSC2; CTRP2 -1.2879 1.1902 -1.296 42.2103
SNU-C4 CTRP1 -1.1474 6.0416 -2.9796 47.9489
HCT 15 GDSC2 -0.83 3.0169 -1.544 27.9455
SNU-81 GDSC2; CTRP2; CTRP1 -0.8136 3.6234 -1.0242 39.6027
KM12 GDSC2; CTRP2; CTRP1 -0.5212 3.2375 -0.6486 37.4657
HCC2998 GDSC2 -0.1975 3.2499 -0.9757 22.1861
SNU-C5 GDSC2; CTRP2; CTRP1 -0.0263 4.7663 -0.416 34.986
CCK-81 GDSC2; CTRP2 0.1474 7.364 -1.0737 36.084
COLO205 GDSC2; CTRP2 0.1809 3.7536 0.0252 32.9115
SW948 GDSC2; CTRP1 0.2418 6.5989 -1.8593 27.8859
CL-11 GDSC2; CTRP2 0.2515 6.3433 -0.5909 34.4917
SW620 GDSC2; CTRP2; CTRP1 0.5589 3.1969 0.5029 30.0705
RKO GDSC2; CTRP2; CTRP1 0.6077 4.3616 0.3703 30.3528
HT-55 GDSC2; CTRP2; CTRP1 0.7523 2.755 0.7361 28.6487
CaR-1 GDSC2 0.7546 5.0103 -0.8609 17.9088
LS180 GDSC2; CTRP2; CTRP1 0.8353 6.4467 0.0038 30.7897
SNU-1040 GDSC2; CTRP1 1.1104 5.6639 -0.5844 18.6167
RCM-1 [Human ESC] GDSC2; CTRP1 1.1251 3.902 0.2777 13.6655
GP5d GDSC2 1.3245 7.3893 -1.537 19.7256
HT115 GDSC2; CTRP2; CTRP1 1.3738 5.8041 0.808 26.4221
DLD-1 CTRP2 1.4253 3.588 1.3767 24.2746
CL-40 CTRP1 1.4392 6.7174 -0.805 26.1688
LS513 GDSC2; CTRP2 1.4555 6.6022 0.6142 26.8437
HT-29 GDSC2; CTRP2; CTRP1 1.4851 3.0994 1.4736 23.7512
LS123 GDSC2; CTRP2; CTRP1 1.5157 3.8782 1.4378 23.7725
LS411N GDSC2; CTRP2 1.6763 4.3997 1.5225 22.966
SW626 GDSC2 1.7065 7.1866 -1.1152 16.3111
SNU-61 GDSC2; CTRP2; CTRP1 1.773 5.5975 1.3092 23.4283
SW480 CTRP1 2.0798 5.651 0.2802 15.6389
DiFi GDSC2 2.1087 6.8732 -0.6364 12.4416
SNU-407 GDSC2; CTRP2 2.1333 8.277 0.6396 24.7822
SW1417 GDSC2 2.1361 6.1644 -0.2632 10.1347
NCI-H716 GDSC2 2.2878 8.634 -1.3723 16.0653
C2BBe1 GDSC2 2.4456 12.1578 -3.0024 22.9629
NCI-H508 CTRP2; CTRP1 2.4739 7.8661 1.1692 21.9395
COLO 320HSR GDSC2 2.5139 4.4476 0.8338 2.6373
SW1116 GDSC2 2.5299 10.2013 -1.9633 18.3574
SW1463 GDSC2 2.7333 6.1799 0.1597 6.1677
MDST8 GDSC2; CTRP2; CTRP1 2.7628 9.2315 0.8402 22.3738
SNU-C2A CTRP2 2.8346 7.2488 1.8094 18.5451
SNU-C2B GDSC2 2.9092 10.2055 -1.6776 16.0172
SW837 GDSC2 2.9542 5.6335 0.556 3.4457
HCT 8 CTRP1 3.0401 6.0869 0.7924 7.8739
COLO 320 CTRP1 3.0852 6.4748 0.6366 9.022
OUMS-23 CTRP2 3.1746 5.7069 2.791 13.8402
HCT 116 GDSC2; CTRP2; CTRP1 3.3111 7.3753 2.2409 15.6116
COLO 678 GDSC2; CTRP1 3.3614 8.5157 -0.1589 10.0424
CW-2 GDSC2; CTRP2; CTRP1 3.6099 10.0143 1.2819 18.6368
SNU-C1 GDSC2 3.6351 5.6246 0.9115 0.8983
LS1034 GDSC2 3.8167 5.5611 1.0112 0.4652
NCI-H747 GDSC2 4.1846 6.5915 0.7758 0.9792
T84 GDSC2 4.3889 6.3631 0.9426 0.3894
⏷ Show the Full List of 56 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC2 1.0428 4.4532 -0.3227 13.7167
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HLE GDSC2 -1.9564 1.8737 -2.3624 37.2596
Li-7 CTRP2 -0.726 2.7138 -0.8026 38.6729
SNU-878 CTRP2 -0.3092 3.9522 -0.5403 36.3707
SK-HEP-1 GDSC2 0.5753 6.6373 -1.8252 23.6602
JHH-7 GDSC2 0.5851 7.0999 -2.0445 24.6494
JHH-4 GDSC2 0.6837 6.1349 -1.4788 21.5511
Hep 3B2.1-7 GDSC2; CTRP2 0.8037 2.2671 0.8014 28.26
SNU-398 GDSC2; CTRP2; CTRP1 0.8115 7.1406 -0.2788 31.7238
JHH-2 GDSC2 0.8187 5.6409 -1.1124 19.114
SNU-423 GDSC2 1.5821 7.5962 -1.423 18.3413
JHH-6 GDSC2; CTRP1 1.5984 3.1916 0.7928 4.9764
SNU-886 CTRP2 1.6795 5.8769 0.3799 16.342
HuH-6 CTRP2 1.8753 4.8585 1.6348 21.9481
JHH-1 GDSC2 2.2527 4.8352 0.4771 5.2931
Hep-G2/C3A GDSC2 2.5254 6.3913 -0.0867 8.1069
SNU-182 CTRP2 2.6431 5.5582 2.2674 17.3371
Hep-G2 CTRP2; CTRP1 3.0176 7.334 1.9605 17.4746
HuH-1 GDSC2 3.1296 8.7657 -0.8138 10.9534
Huh-7 GDSC2 3.1396 5.6221 0.6674 2.5532
SNU-761 CTRP2 3.2001 7.6796 1.9911 16.8814
SNU-387 GDSC2 3.9438 16.7472 -4.1314 23.2259
SNU-449 GDSC2; CTRP1 4.4148 6.7717 0.8038 0.7432
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 173 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H1184 CTRP2 -4.989 1.8115 -5.2221 63.8705
NCI-H1105 CTRP1 -4.1836 0.2123 -4.3529 75.5043
NCI-H1876 GDSC2; CTRP1 -3.9294 -0.8711 -3.9666 57.0104
NCI-H1734 CTRP2 -3.6063 1.1831 -3.6872 57.1396
NCI-H526 GDSC2; CTRP2 -3.3074 -1.8547 -3.3074 55.6409
NCI-H1694 GDSC2; CTRP1 -3.1149 -1.0174 -3.1233 49.5658
NCI-H2081 CTRP1 -3.0543 4.9784 -4.5217 60.1281
NCI-H209 GDSC2 -2.8641 -0.6419 -2.8887 44.7274
SBC-5 GDSC2; CTRP2 -2.8025 -1.0681 -2.8026 52.2769
NCI-H596 GDSC2; CTRP1 -2.7336 2.2155 -3.2149 46.6466
NCI-H1048 GDSC2 -2.6195 0.5068 -2.7605 42.6702
NCI-H211 GDSC2; CTRP2 -2.5094 1.0101 -2.5378 50.3184
NCI-H1623 GDSC2 -2.27 0.5851 -2.3973 39.2215
NCI-H1963 GDSC2; CTRP1 -2.2154 1.4752 -2.4603 41.7567
NCI-H1155 GDSC2; CTRP2 -1.8297 0.293 -1.8312 45.7998
SBC-3 GDSC2 -1.6839 2.209 -2.1704 35.0101
NCI-H1651 GDSC2 -1.553 4.9415 -3.1071 37.4927
NCI-H82 GDSC2 -1.5226 2.7831 -2.1953 34.2625
EMC-BAC-2 GDSC2 -1.5092 6.6647 -3.8389 39.0737
DMS 79 GDSC2; CTRP2 -1.4971 4.303 -1.9066 44.3002
Lu-99 CTRP2 -1.4934 2.9629 -1.6487 43.8773
HCC15 GDSC2; CTRP2; CTRP1 -1.48 4.967 -2.0549 44.4202
NCI-H1930 CTRP1 -1.4557 2.6078 -2.6249 29.8723
HCC78 GDSC2; CTRP2 -1.4514 2.0355 -1.5035 43.4018
NCI-H2286 CTRP2; CTRP1 -1.4274 2.9607 -1.5779 43.4432
NCI-H2073 CTRP1 -1.338 8.3471 -4.2258 49.444
IST-SL2 GDSC2 -1.2182 1.0322 -1.3429 28.7655
SK-LU-1 GDSC2; CTRP2; CTRP1 -1.1592 6.4252 -2.1476 43.1298
NCI-H2009 CTRP2 -1.0336 3.5031 -1.2404 41.0179
NCI-H2810 GDSC2 -1.0141 5.3453 -2.739 33.813
NCI-H2795 GDSC2 -0.8972 4.9485 -2.4414 32.2089
A-427 GDSC2 -0.802 5.173 -2.4475 31.8084
Calu-3 GDSC2; CTRP2 -0.6951 7.0222 -1.8524 40.7948
DMS 53 GDSC2 -0.6561 4.044 -1.793 28.3704
SCLC-21H CTRP1 -0.6296 3.7835 -1.4765 41.9176
NCI-H23 GDSC2 -0.6123 4.7359 -2.0578 29.3794
COR-L311 GDSC2 -0.5825 3.5094 -1.4861 26.5474
Ms-1 GDSC2 -0.4505 3.7345 -1.4465 25.7743
NCI-H1838 CTRP2 -0.3887 2.978 -0.4746 36.4665
LXF 289 GDSC2; CTRP2; CTRP1 -0.343 4.5718 -0.713 36.9746
HCC44 GDSC2; CTRP2 -0.3321 2.8187 -0.398 36.0295
NCI-H2170 GDSC2 -0.3199 2.3091 -0.7285 21.3259
EBC-1 GDSC2; CTRP2 -0.2957 3.3494 -0.4234 35.9776
NCI-H2227 GDSC2 -0.2804 7.5839 -3.0823 31.9067
COLO 668 GDSC2; CTRP1 -0.2334 2.1939 -0.5937 20.1954
CPC-N GDSC2 -0.2292 3.6375 -1.1768 23.4213
LCLC-97TM1 GDSC2; CTRP2 -0.2142 3.558 -0.3677 35.5174
DMS 273 GDSC2 -0.1664 4.1619 -1.3483 24.0784
NCI-H1781 GDSC2; CTRP1 -0.1589 4.218 -1.1648 26.3596
LK-2 GDSC2 -0.1041 12.5019 -5.3379 36.789
NCI-H358 GDSC2; CTRP2 -0.0933 4.2645 -0.3705 35.093
NCI-H2029 GDSC2 -0.0853 2.4348 -0.5242 19.1645
SW1573 GDSC2 -0.067 3.856 -1.1093 22.3908
SK-MES-1 GDSC2 -0.0608 5.0133 -1.6391 25.1391
NCI-H1975 GDSC2; CTRP2 -0.0463 2.2099 -0.0607 33.9626
NCI-H2087 GDSC2; CTRP2 -0.0436 5.5963 -0.6683 35.7495
NCI-H810 GDSC2 0.0422 4.8392 -1.4564 23.8091
Lu-139 GDSC2 0.0554 5.0916 -1.5631 24.3024
RERF-LC-A1 CTRP2 0.0616 4.5951 -0.2777 34.2664
Lu-65 GDSC2 0.0669 3.5614 -0.8412 20.3535
NCI-H3122 GDSC2 0.0954 4.5597 -1.2727 22.6348
NCI-H1581 GDSC2; CTRP2 0.1584 2.8884 0.1107 32.7092
HARA [Human squamous cell lung carcinoma] GDSC2; CTRP2 0.1705 5.0878 -0.2865 33.9104
PC-14 GDSC2; CTRP2 0.1989 3.9969 0.0011 32.9272
Lu-135 GDSC2 0.2259 6.9092 -2.2801 26.9804
ABC-1 GDSC2 0.2761 5.2148 -1.4099 22.6705
NCI-H661 GDSC2; CTRP2 0.2915 4.1851 0.0643 32.4094
NCI-H2804 GDSC2 0.3391 5.127 -1.3076 21.8932
NCI-H2126 CTRP2 0.373 6.1917 -0.4074 33.5598
NCI-H2461 GDSC2 0.3823 7.6022 -2.4766 27.2244
COR-L51 CTRP1 0.4906 1.6601 0.4374 22.7931
HCC2108 CTRP2; CTRP1 0.5302 3.0869 0.4831 30.2317
A-549 GDSC2; CTRP2 0.5707 5.9415 -0.1094 32.0097
NCI-H446 GDSC2; CTRP2 0.5971 5.7589 -0.0215 31.6509
NCI-H2228 GDSC2; CTRP2 0.6027 7.5784 -0.6711 33.5125
HOP-62 GDSC2 0.6037 4.5068 -0.757 17.8381
SW1271 GDSC2; CTRP2 0.6454 6.3016 -0.1502 31.8849
NCI-H322M GDSC2 0.663 3.9451 -0.4302 15.6841
HCC366 GDSC2; CTRP2 0.6777 4.2473 0.4705 29.7885
Lu-99A GDSC2 0.6816 6.9898 -1.9029 23.6565
NCI-H69 CTRP2 0.748 4.8666 0.403 29.7842
Sq-1 CTRP2; CTRP1 0.7632 2.8063 0.7448 28.5837
NCI-H460 CTRP2; CTRP1 0.7865 5.5033 0.2647 30.1149
NCI-H1299 GDSC2; CTRP2 0.8813 5.2906 0.4315 29.2574
MOR/CPR CTRP2 0.909 1.4648 0.909 27.5509
HCC95 CTRP2 1.0419 3.5811 0.9716 26.9024
HCC827 GDSC2; CTRP2; CTRP1 1.0628 5.3109 0.6235 28.0295
NCI-H524 GDSC2 1.0726 7.4959 -1.8077 21.8835
NCI-H2373 GDSC2 1.1193 4.4734 -0.2636 13.1021
NCI-H841 GDSC2; CTRP1 1.1826 7.162 -1.2552 21.8382
NCI-H2023 GDSC2; CTRP2; CTRP1 1.2148 7.0975 0.168 29.0668
NCI-H250 GDSC2 1.2483 7.5572 -1.6862 20.7206
NCI-H650 GDSC2; CTRP2 1.2705 6.6507 0.3977 28.1423
NCI-H1650 GDSC2; CTRP2 1.3054 4.8647 1.0116 25.9223
NCI-H3255 GDSC2; CTRP1 1.3146 5.505 -0.3179 16.4615
NCI-H720 GDSC2 1.3366 9.0361 -2.3496 23.5116
COR-L23 GDSC2; CTRP1 1.3863 5.2981 -0.1505 15.2753
HCC1195 CTRP2; CTRP1 1.4675 5.3508 1.0531 25.2727
LCLC-103H GDSC2; CTRP2 1.4684 2.3138 1.4684 23.8238
Calu-6 GDSC2; CTRP2 1.4878 3.549 1.4464 23.8341
NCI-H292 CTRP2 1.5136 5.4459 1.0745 25.0555
NCI-H2030 CTRP2; CTRP1 1.5156 7.4646 0.3409 27.5857
NCI-H1944 GDSC2 1.5385 5.0367 -0.1798 11.2778
NCI-H2405 GDSC2; CTRP2 1.6101 6.0718 0.9729 25.1229
NCI-H2595 GDSC2 1.6152 5.5039 -0.3494 12.0971
NCI-H2291 CTRP2 1.6461 10.6847 -0.9409 31.008
NCI-H2731 GDSC2 1.6953 5.3407 -0.2018 10.9576
HCC1359 CTRP1 1.6994 3.749 0.8983 12.0393
NCI-H1793 GDSC2 1.7079 5.5862 -0.3141 11.6129
HCC4006 CTRP1 1.7842 4.0786 0.8119 12.4071
NCI-H1993 GDSC2 1.8133 5.5527 -0.2119 10.6875
CAL-12T CTRP2; CTRP1 1.8174 3.4353 1.7993 21.5594
NCI-H2818 GDSC2 1.855 8.1908 -1.4957 17.9142
NCI-H226 GDSC2; CTRP2 1.8823 5.5013 1.4587 22.5596
HCC1833 CTRP2; CTRP1 1.888 5.6491 1.4175 22.6915
RERF-LC-Sq1 GDSC2 1.9674 4.2077 0.5771 5.3518
NCI-H522 GDSC2 2.0082 6.964 -0.7605 13.4393
HCC1588 CTRP2 2.033 7.1637 1.0085 23.7553
NCI-H441 GDSC2; CTRP2; CTRP1 2.0483 9.8315 -0.1469 27.607
NCI-H1355 GDSC2; CTRP2 2.056 6.7915 1.1824 23.0578
COLO 699 CTRP2; CTRP1 2.0574 5.0505 1.7829 20.859
NCI-H1836 CTRP1 2.0638 5.2063 0.4893 13.9754
NCI-H2803 GDSC2 2.0717 5.1528 0.1886 7.5146
NCI-H1869 GDSC2 2.0778 4.8741 0.3309 6.6137
HCC2935 CTRP1 2.1779 5.8139 0.2797 15.2332
NCI-H2106 CTRP2 2.2 6.252 1.5433 21.3142
UMC-11 GDSC2 2.2001 6.9097 -0.5837 11.8893
NCI-H1915 GDSC2; CTRP1 2.2327 4.6801 0.5384 4.9626
NCI-H520 GDSC2; CTRP2 2.2335 5.0998 1.9615 19.6788
NCI-H513 GDSC2 2.2594 6.237 -0.2057 9.4706
T3M-10 CTRP1 2.3012 5.0108 0.7797 10.5161
LC-1/sq GDSC2 2.3208 9.4095 -1.7322 17.8051
NCI-H196 GDSC2; CTRP2 2.3629 5.5013 1.9816 19.2174
EPLC-272H GDSC2; CTRP2 2.386 10.1769 0.0272 26.137
IA-LM GDSC2 2.4058 4.9705 0.5178 4.7089
NCI-H2342 CTRP1 2.4309 8.5977 -0.9059 22.4224
NCI-H1435 GDSC2; CTRP2; CTRP1 2.4466 5.0256 2.2145 18.118
NCI-H2135 GDSC2 2.5592 6.6952 -0.2108 8.7743
NCI-H2591 GDSC2 2.6188 8.3854 -0.9968 13.1801
NCI-H2369 GDSC2 2.6301 9.5238 -1.5506 16.0857
NCI-H2444 CTRP2 2.6916 5.0505 2.4751 16.4319
NCI-H889 CTRP2 2.7026 6.5939 1.946 18.3796
NCI-H1092 GDSC2 2.7028 8.1101 -0.7994 11.8691
HOP-92 GDSC2 2.7552 10.1762 -1.7787 16.8961
NCI-H345 GDSC2 2.7893 3.6804 1.2935 0.2038
VMRC-LCD GDSC2 2.7903 5.2493 0.6332 3.2916
NCI-H2141 GDSC2; CTRP1 2.8044 8.9857 -0.8045 14.8441
NCI-H2722 GDSC2 2.8151 9.0993 -1.2028 13.8134
LOU-NH91 GDSC2; CTRP2 2.8628 9.6699 0.7324 22.5014
SHP-77 GDSC2; CTRP2 2.938 5.4744 2.6153 15.1831
NCI-H2869 GDSC2 3.0223 9.7596 -1.3752 14.2164
KNS-62 GDSC2 3.0858 7.123 -0.0554 6.7109
NCI-H1666 GDSC2; CTRP2 3.1279 10.4133 0.6332 22.1838
NCI-H1693 GDSC2 3.1283 4.9894 0.932 1.2741
RERF-LC-KJ GDSC2; CTRP1 3.1654 7.829 -0.3384 8.1846
NCI-H2110 CTRP1 3.1707 13.8111 -2.9183 28.5892
EKVX GDSC2 3.1927 10.7219 -1.7227 15.5517
COR-L105 GDSC2 3.2355 11.884 -2.2621 17.9459
NCI-H1792 GDSC2; CTRP2 3.2479 7.5221 2.1108 16.2877
NCI-H1373 CTRP2 3.4722 7.3503 2.4146 14.5111
DMS 114 GDSC2 3.4768 11.0012 -1.6549 14.5617
NCI-H2085 GDSC2; CTRP2 3.5191 12.4685 -0.0046 23.3902
NCI-H1568 GDSC2 3.6632 19.9173 -5.912 28.4513
HCC2279 CTRP2 3.6825 7.0439 2.7655 12.5773
Lu-165 GDSC2 4.0984 14.4566 -2.8954 18.6023
NCI-H1563 GDSC2 4.6297 15.5678 -3.0603 18.1172
NCI-H727 GDSC2; CTRP2 4.7521 8.5738 3.0306 9.0441
NCI-H2172 CTRP2; CTRP1 4.7813 6.7295 3.9736 5.0358
BEN CTRP2 5.1484 5.9441 4.678 1.3508
RERF-LC-Ad1 CTRP2 5.1824 8.0682 3.6459 5.6175
NCI-H2122 GDSC2; CTRP2; CTRP1 5.6107 14.9521 0.5542 17.0922
HCC1171 CTRP2 6.313 13.6686 1.7385 11.4593
NCI-H1755 GDSC2; CTRP2; CTRP1 6.37 15.7207 0.7667 14.975
⏷ Show the Full List of 173 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC2 -1.3228 1.7685 -1.6404 30.7696
Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A2780 GDSC2; CTRP2; CTRP1 -4.0706 4.4422 -4.7453 57.9728
OVKATE CTRP1 -3.419 5.859 -5.2601 60.9141
TOV-112D GDSC2 -2.8913 -0.1716 -2.9561 45.103
OVK18 GDSC2; CTRP2; CTRP1 -1.8482 4.1477 -2.2531 46.4129
Caov-3 CTRP2; CTRP1 -1.348 1.7928 -1.3803 42.6723
OVCAR-8 GDSC2; CTRP2; CTRP1 -0.9034 2.2297 -0.9468 39.7541
TOV-21G GDSC2 -0.7924 8.9899 -4.2468 37.0039
JHOC-5 CTRP2; CTRP1 -0.6708 4.6169 -1.0814 39.1682
DOV13 GDSC2; CTRP2 -0.5801 4.6238 -0.9842 38.5777
ES-2 GDSC2 -0.5295 4.6114 -1.9179 28.3987
TYK-nu GDSC2; CTRP2; CTRP1 -0.5008 3.7714 -0.7133 37.5708
COV434 CTRP1 -0.2213 5.8771 -1.9726 40.3756
MCAS CTRP2 -0.2003 2.9538 -0.2728 35.1747
OV-90 GDSC2; CTRP1 0.4545 3.9159 -0.402 19.9674
FU-OV-1 CTRP2 0.491 3.9784 0.3204 30.9043
EFO-27 GDSC2; CTRP1 0.5021 3.0509 0.0144 17.4878
OV7 CTRP1 0.5565 3.9032 -0.2923 27.7781
OV56 GDSC2 0.7849 3.8255 -0.2562 14.1939
HEY A8 CTRP2 0.9082 7.289 -0.233 31.2761
IGROV-1 GDSC2; CTRP2; CTRP1 1.0496 5.8898 0.4277 28.7329
SNU-119 CTRP2 1.051 3.8055 0.9514 26.9415
RMUG-S CTRP1 1.1415 4.8526 -0.1606 23.5069
JHOS-4 CTRP1 1.2175 5.92 -1.9712 13.3158
ONCO-DG-1 CTRP2 1.3337 2.479 1.3328 24.7241
OVCAR-5 GDSC2 1.3759 5.0766 -0.338 12.7451
OAW42 GDSC2; CTRP1 1.5992 4.258 0.5561 10.4417
OVCAR-3 GDSC2 1.694 4.4105 0.262 8.0607
JHOM-1 CTRP1 1.7007 5.3803 0.091 18.8288
ES2 CTRP2 1.7377 5.7559 1.219 23.8592
SNU-8 CTRP2 1.7445 3.8512 1.685 22.1857
EFO-21 GDSC2 1.9002 5.703 -0.2176 10.4827
SK-OV-3 GDSC2; CTRP2 1.9825 7.5811 0.7827 24.7065
COV318 CTRP1 1.9826 3.1358 -0.3115 0.1888
COV362 CTRP1 2.2897 9.8545 -1.6482 26.79
OVSAHO CTRP2 2.3139 4.5211 2.1894 18.6187
OAW28 GDSC2; CTRP2 2.4128 5.71 1.9666 19.126
SNU-840 CTRP2; CTRP1 2.4303 6.5706 1.6669 20.1965
RMG-I CTRP2; CTRP1 2.4571 7.254 1.4155 21.0674
OVISE GDSC2; CTRP2 2.7343 5.6338 2.3409 16.7974
COV644 CTRP1 3.0698 5.2267 1.2172 4.2782
OVCAR-4 GDSC2; CTRP2; CTRP1 3.17 5.151 2.9687 13.1956
Kuramochi GDSC2; CTRP2 4.1635 7.4229 3.0597 10.2134
OVMANA CTRP1 4.7325 13.3424 -3.2106 12.0319
OVTOKO GDSC2; CTRP2 4.9854 9.5522 2.7411 9.7856
⏷ Show the Full List of 44 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 32 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KP-4 GDSC2; CTRP2 -1.9803 1.3007 -2.0071 46.8421
L3.3 CTRP2 -1.895 0.4537 -1.8983 46.2386
MIA PaCa-2 GDSC2 -1.2745 1.8769 -1.62 30.4313
PSN1 GDSC2 -0.3603 2.7244 -0.9298 22.6198
PaTu 8988t GDSC2 -0.3562 3.4264 -1.2158 24.163
HuP-T4 GDSC2; CTRP2 0.1335 5.9349 -0.5822 34.8824
Capan-1 GDSC2 0.396 4.1046 -0.7644 18.6424
QGP-1 GDSC2; CTRP2 0.4586 4.2719 0.2275 31.3181
HPAC GDSC2; CTRP2 0.5311 2.7349 0.509 30.1422
Panc 02.03 GDSC2 0.8934 11.529 -3.9745 30.5916
HuP-T3 GDSC2 1.1836 4.8852 -0.4105 13.794
YAPC GDSC2; CTRP2 1.2658 6.3434 0.5051 27.7963
DAN-G GDSC2 1.4505 5.9042 -0.6876 14.6259
PK-59 CTRP2 1.4849 4.9792 1.1774 24.7795
KP-3 GDSC2; CTRP2 1.7251 4.843 1.4749 22.9811
KP-1N GDSC2 1.7517 3.8732 0.5767 5.9154
PL4 GDSC2 1.7562 6.7854 -0.8739 14.8052
Panc 10.05 GDSC2 1.7895 7.6311 -1.2694 16.9104
SUIT-2 GDSC2; CTRP2 2.0737 8.3431 0.5494 25.2616
TCC-Pan2 CTRP2 2.1243 5.6843 1.6625 21.0954
PaTu 8902 GDSC2; CTRP2; CTRP1 2.1484 6.0796 1.5511 21.4347
KP-2 GDSC2 2.1595 5.4596 0.1031 7.8251
Capan-2 GDSC2 2.2751 9.9953 -2.0598 19.4873
SU.86.86 GDSC2; CTRP2 2.4612 4.5084 2.3514 17.5861
BxPC-3 GDSC2; CTRP2 2.5528 7.2061 1.5354 20.3534
CFPAC-1 GDSC2; CTRP2 2.8785 7.7271 1.6443 19.0648
Panc 08.13 GDSC2 3.2505 8.2838 -0.4987 8.9206
AsPC-1 GDSC2 3.7766 6.6676 0.5541 2.285
HPAF-II GDSC2; CTRP2 4.23 7.7509 2.9642 10.4523
SNU-410 CTRP2 4.544 13.6947 0.2955 20.1101
SNU-213 CTRP2 4.9465 8.0673 3.4506 6.8904
Panc 05.04 CTRP2 6.7336 17.2831 0.2695 16.0647
⏷ Show the Full List of 32 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H28 GDSC2; CTRP2 -1.8713 0.9645 -1.8834 46.0977
MSTO-211H GDSC2; CTRP2 -1.6748 5.2748 -2.3526 45.6638
NCI-H2452 CTRP2 0.5 8.8118 -1.2818 35.3666
NCI-H2052 GDSC2; CTRP2 0.6161 6.6791 -0.316 32.4747
MPP 89 GDSC2 1.3979 3.8717 0.2822 8.8066
ACC-MESO-1 CTRP2 1.6216 4.156 1.5087 23.188
IST-Mes1 GDSC2 3.2104 14.3659 -3.5066 22.8617
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LNCaP clone FGC GDSC2 -0.4566 5.9923 -2.4875 30.4895
22Rv1 GDSC2; CTRP2 -0.3532 4.9623 -0.8239 37.3034
DU145 GDSC2 0.1597 3.7872 -0.8502 20.0396
PaCa-3 CTRP1 0.407 2.171 -0.7229 5.7096
VCaP GDSC2 0.9599 7.4914 -1.9041 22.7161
PC-3 GDSC2 1.2741 6.5389 -1.1556 17.8535
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-15 CTRP2 -0.5403 2.469 -0.586 37.3502
A-253 GDSC2 -0.4982 4.0882 -1.651 27.0032
Cancer Drug Sensitivity Data Curated from 43 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Hs 944.T CTRP2 -2.535 3.6112 -2.8846 50.4318
A2058 GDSC2 -1.431 2.0839 -1.8551 32.3272
A-375 GDSC2; CTRP2; CTRP1 -0.9867 4.0959 -1.3049 40.9621
IGR-37 GDSC2 -0.861 3.9682 -1.9712 30.1029
IPC-298 CTRP2 -0.6033 3.2726 -0.7413 38.0365
G-361 GDSC2; CTRP2 -0.5364 4.8156 -0.9851 38.4089
WT2-iPS GDSC2 -0.5311 5.9294 -2.5304 30.9632
LOX-IMVI GDSC2; CTRP2 -0.5217 6.6846 -1.5457 39.5644
RPMI-7951 GDSC2; CTRP2 -0.467 3.5096 -0.6315 37.2151
UACC-62 GDSC2 -0.4493 2.6453 -0.9937 23.3573
HT-144 GDSC2 0.21 7.2274 -2.4506 27.7453
CHL-1 GDSC2 0.2719 3.8519 -0.7682 19.134
SK-MEL-24 GDSC2 0.4241 8.3446 -2.8051 28.3493
G-mel GDSC2 0.4461 3.503 -0.4338 16.5057
A101D GDSC2 0.4508 5.9641 -1.6092 23.0474
HMV-II GDSC2 0.4847 5.5508 -1.3759 21.7215
Hs 852.T CTRP2; CTRP1 0.9121 6.7371 -0.019 30.613
M14 GDSC2 1.0349 5.9605 -1.0766 18.1876
Hs 936.T CTRP2 1.3188 6.515 0.4998 27.6509
SK-MEL-5 GDSC2; CTRP2; CTRP1 1.3814 5.4318 0.9347 25.9551
SK-MEL-30 CTRP2 1.4414 4.7829 1.1805 24.9044
WM1552C GDSC2 1.4842 6.9704 -1.1922 17.4013
Mel Ho CTRP2 1.768 5.6616 1.283 23.5376
GAK GDSC2 1.7785 4.5717 0.2497 7.904
WM35 GDSC2 1.8093 5.0176 0.0518 9.0606
WM793 GDSC2; CTRP2 1.8407 7.8398 0.5258 26.0064
COLO 741 CTRP2 1.9232 5.9014 1.3708 22.757
WM1799 CTRP2 2.1539 6.4747 1.4099 21.9408
SK-MEL-1 CTRP2; CTRP1 2.1764 9.4076 0.1756 26.2284
Mel JuSo GDSC2; CTRP2 2.1854 5.6141 1.752 20.5864
WM278 GDSC2 2.3231 6.2451 -0.1622 9.0482
IGR-1 GDSC2 2.3667 7.7753 -0.8853 13.1982
CP66-MEL GDSC2 2.5077 8.7887 -1.2798 14.9967
SH-4 GDSC2 2.5541 9.5242 -1.6088 16.5749
COLO 679 GDSC2 2.6781 8.9692 -1.2405 14.3536
WM115 GDSC2 2.7519 12.0531 -2.7112 21.0348
SK-MEL-2 GDSC2 2.9343 3.8579 1.2852 0.1668
UACC-257 GDSC2 2.9479 6.3944 0.1991 5.5016
MDA-MB-435S CTRP2 3.255 7.1525 2.2834 15.5883
COLO 792 GDSC2 3.5548 15.1402 -3.6292 22.4756
COLO 829 GDSC2 4.0714 16.8179 -4.0717 22.7661
SK-MEL-28 CTRP2; CTRP1 4.5684 8.188 3.0602 9.3053
SK-MEL-31 CTRP2 5.0406 8.6039 3.2615 7.5002
⏷ Show the Full List of 43 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC2 -1.6848 2.6285 -2.3144 35.5837
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
EW-8 GDSC2 -4.6282 -2.1417 -4.6375 61.9912
G-401 GDSC2 -2.9805 6.0231 -5.0483 47.7299
KYM-1 GDSC2 -1.528 2.6295 -2.1456 34.0883
SW982 GDSC2 -1.2175 5.5766 -3.0487 35.7334
SK-UT-1 GDSC2 -0.9839 2.0931 -1.3721 27.7902
Rh41 GDSC2; CTRP2 -0.9636 1.953 -0.992 40.1112
SK-LMS-1 GDSC2 -0.7048 3.72 -1.7029 28.1578
HT-1080 GDSC2; CTRP1 -0.5822 4.7328 -1.8244 31.1014
G-402 GDSC2 -0.4658 7.1791 -3.0627 32.5687
GCT GDSC2 -0.1695 3.2516 -0.9474 21.9119
SW872 GDSC2 0.3928 3.8356 -0.6412 17.9341
Rh30 GDSC2 0.9563 4.7211 -0.5336 15.2865
A-204 GDSC2 1.0241 8.054 -2.1281 23.5369
VA-ES-BJ GDSC2 1.0774 4.7884 -0.4572 14.4231
MES-SA GDSC2 1.5301 10.7265 -3.0316 25.6275
RKN GDSC2; CTRP2; CTRP1 1.6916 5.0277 1.3899 23.387
RD GDSC2 2.3145 6.5134 -0.3008 9.9083
SW684 GDSC2 2.4503 8.4453 -1.1534 14.4671
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
AGS GDSC2; CTRP2; CTRP1 -2.6501 2.7736 -2.8595 51.1463
GSS CTRP2 -1.8522 2.1477 -1.9328 46.078
RF-48 GDSC2 -1.7408 10.3721 -5.8152 43.0027
ECC10 GDSC2; CTRP2 -1.737 2.0886 -1.8064 45.3097
23132/87 GDSC2; CTRP2 -1.6111 1.9548 -1.664 44.4549
MKN1 GDSC2; CTRP2 -1.3393 3.6651 -1.6 43.0822
NUGC-3 GDSC2; CTRP2 -1.2832 2.1083 -1.3335 42.2872
SNU-5 GDSC2; CTRP2 -1.0741 2.3597 -1.1352 40.9326
NCI-N87 GDSC2; CTRP2 -0.7849 3.8517 -1.0358 39.5161
ECC12 CTRP2 -0.6561 1.1498 -0.6577 37.9826
SNU-668 CTRP2 -0.2992 3.0521 -0.3883 35.8831
SNU-1 GDSC2 -0.0039 6.136 -2.1203 27.1623
SNU-620 CTRP2 0.1859 2.3106 0.1733 32.4098
HGC-27 GDSC2 0.2809 6.0786 -1.8236 24.722
SK-GT-2 GDSC2 0.7739 5.4821 -1.0749 19.0589
GCIY GDSC2 0.9633 6.3445 -1.3308 19.8159
KATO III GDSC2 1.3205 3.0143 0.6395 6.802
NUGC-4 GDSC2; CTRP2 1.4184 6.6407 0.56 27.1419
Hs 746.T GDSC2 1.7377 5.596 -0.2948 11.4097
RERF-GC-1B GDSC2 1.801 8.008 -1.4483 17.8252
OCUM-1 GDSC2 2.3139 6.0529 -0.0745 8.5361
MKN74 CTRP2; CTRP1 2.546 5.1705 2.2824 17.5707
MKN28 GDSC2 2.5635 5.9996 0.1304 6.7094
Fu97 CTRP2 3.213 4.9879 3.0609 12.7314
GSU CTRP2 3.5535 5.2435 3.3589 10.6216
SNU-719 CTRP2 3.7993 9.9739 1.4781 17.4413
KE-39 CTRP2 4.234 8.3299 2.6855 11.5925
IM95 GDSC2 4.5883 19.0418 -4.7845 23.7855
MKN45 GDSC2; CTRP2 5.0158 6.0038 4.5407 2.173
SNG-M GDSC2; CTRP2; CTRP1 1.255 4.749 0.9857 26.1714
SNU-1077 CTRP2 2.526 4.8536 2.3457 17.4041
⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IHH-4 GDSC2 -1.9784 2.1651 -2.4765 37.7977
ML-1 [Human leukemia] CTRP2 -1.4814 4.7007 -1.9865 44.3367
ASH-3 GDSC2 -1.006 2.0648 -1.3868 27.9696
CGTH-W-1 CTRP2 -0.6608 2.533 -0.7171 38.1819
BHT-101 GDSC2; CTRP2 -0.6394 3.6132 -0.8346 38.4292
8505C GDSC2; CTRP2 -0.5699 2.9563 -0.6641 37.6909
TT2609-C02 GDSC2 0.2105 5.8369 -1.7724 24.7403
CAL-62 GDSC2; CTRP2 0.2112 5.2614 -0.291 33.7818
FTC-133 GDSC2 0.2569 5.1814 -1.4122 22.7543
B-CPAP GDSC2; CTRP2 0.6787 4.6519 0.3811 30.0837
8305C GDSC2; CTRP2 1.447 5.2605 1.0574 25.3208
K5 GDSC2 1.6084 8.6841 -1.9451 20.8607
HTC-C3 GDSC2 2.2263 7.5106 -0.8618 13.433
TT CTRP2 3.4993 5.5296 3.2046 11.3531
WRO GDSC2 3.803 11.4857 -1.661 13.8685
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 35 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SAS GDSC2 -3.2261 0.0031 -3.3334 48.3917
BICR 22 GDSC2 -3.1496 0.6576 -3.3616 47.7783
FaDu GDSC2 -2.3907 1.4279 -2.712 41.0357
CAL-33 GDSC2 -2.3669 4.096 -3.602 42.9067
HSC-2 GDSC2 -0.9145 2.4216 -1.4097 27.6575
HO-1-N-1 GDSC2 -0.8296 3.0143 -1.5424 27.936
NCI-H3118 GDSC2 -0.4467 3.4814 -1.3331 25.1705
SNU-1076 CTRP2 -0.3261 4.6508 -0.714 36.914
SCC-9 GDSC2; CTRP1 -0.2002 5.8039 -1.9179 29.8605
OSC-20 GDSC2 -0.1385 4.7088 -1.5726 25.1186
HSC-4 GDSC2; CTRP2 -0.0822 4.7247 -0.4665 35.3322
BICR 10 GDSC2 -0.0237 3.7196 -1.0041 21.6344
CAL-27 GDSC2 0.0359 3.9945 -1.0691 21.7579
HSC-3 GDSC2; CTRP2 0.3734 3.5795 0.2592 31.4987
DOK GDSC2 0.5628 9.1374 -3.0736 28.8368
YD-10B CTRP2 0.7494 7.286 -0.4009 32.2806
UPCI-SCC-090 GDSC2 0.9439 12.2782 -4.3049 31.3337
BHY CTRP2 1.0134 5.9914 0.3545 29.091
BB49-HNC GDSC2 1.0702 10.013 -3.0654 27.1532
JHU-022 GDSC2 1.1761 5.5215 -0.7336 15.7558
YD-8 CTRP2 1.35 4.7612 1.0863 25.5213
Ca9-22 GDSC2 1.423 6.9169 -1.2172 17.7253
PCI-04B GDSC2 1.4767 4.3156 0.1284 9.5355
Detroit 562 GDSC2; CTRP2 1.8494 6.3839 1.1181 23.8914
SCC-15 GDSC2 1.898 9.1021 -1.916 19.8716
SAT [Human HNSCC] GDSC2 1.9379 6.6287 -0.6491 12.9821
SNU-1066 CTRP2 2.155 5.689 1.6942 20.8881
BICR 78 GDSC2 2.342 8.5515 -1.2892 15.4812
SKN-3 GDSC2 2.4419 6.7392 -0.3176 9.6944
SCC-4 GDSC2 2.7442 9.4974 -1.4516 15.2915
SNU-46 CTRP2 2.8462 9.2239 0.9259 21.8477
SNU-1214 CTRP2 2.9316 5.5203 2.5931 15.2838
SNU-899 CTRP2 2.9388 7.8859 1.6342 18.9456
LB771-HNC GDSC2 3.6217 10.9325 -1.5195 13.5707
SNU-1041 CTRP2 4.628 8.6489 2.8844 9.9121
⏷ Show the Full List of 35 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JMSU-1 CTRP2 -2.5485 -0.9739 -2.5486 50.5851
UM-UC-3 CTRP2 -1.7744 1.5785 -1.809 45.4965
VM-CUB-1 CTRP2 -0.9995 2.0682 -1.0359 40.3723
RT-112 GDSC2 -0.8993 2.8465 -1.5512 28.3001
5637 GDSC2; CTRP2 -0.7349 3.1505 -0.8646 38.879
647V GDSC2 -0.3469 4.547 -1.7052 26.6263
SW1710 GDSC2; CTRP2 -0.1463 4.5148 -0.485 35.6173
TCCSUP GDSC2; CTRP2 0.4348 3.2324 0.3684 30.9317
CAL-29 GDSC2; CTRP2 0.519 4.3609 0.2741 30.9642
639V GDSC2; CTRP2 0.5235 2.6631 0.5049 30.181
HT-1197 GDSC2 1.0502 6.1678 -1.166 18.6333
SW780 GDSC2 1.1193 4.1898 -0.1233 12.2348
BFTC-905 GDSC2; CTRP2 1.2827 4.2278 1.1298 25.5827
253J CTRP2 1.3041 5.1001 0.9471 26.1521
KU-19-19 GDSC2; CTRP2 1.5185 6.0523 0.8807 25.7255
RT-4 GDSC2; CTRP2 1.5588 5.2282 1.1887 24.5113
J82 GDSC2 1.6798 3.958 0.4765 6.747
HT-1376 CTRP2 3.0474 4.7635 2.9348 13.693
253J-BV CTRP2 3.3949 8.4598 1.8228 17.0553
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NEC8 GDSC2 -4.3487 -2.5023 -4.3501 59.4825
PWR-1E GDSC2 -1.9317 1.461 -2.2198 36.5668
PA-1 GDSC2 -1.6722 4.0472 -2.8501 37.3459
SiSo GDSC2 -1.4775 3.1384 -2.2805 34.3695
ME-180 GDSC2 -1.4594 2.5829 -2.0549 33.3551
C-33 A GDSC2 -1.0115 1.7583 -1.2978 27.5373
Ca Ski GDSC2 -0.6321 4.082 -1.7851 28.228
DSH1 GDSC2 -0.4753 2.4421 -0.9444 23.2013
HT-3 GDSC2 -0.3218 3.0655 -1.0276 22.995
PEO1 GDSC2 -0.3159 3.6419 -1.2676 24.2697
TC-YIK GDSC2 -0.2974 2.2777 -0.6929 21.0288
LB831-BLC GDSC2 -0.0546 5.0483 -1.6495 25.166
CAL-39 GDSC2 0.2147 3.839 -0.8191 19.6477
SKN GDSC2 0.4158 2.646 -0.0814 14.5285
SKG-IIIa GDSC2 0.4235 4.4511 -0.9025 19.3361
HEY GDSC2 0.462 5.3328 -1.291 21.3517
BPH-1 GDSC2 0.5859 7.7374 -2.3589 26.0206
DoTc2 4510 GDSC2 0.6403 3.1075 -0.0579 13.5156
HEC-1 GDSC2 0.6612 2.4039 0.2766 11.431
MS751 GDSC2 0.7407 4.6814 -0.713 17.0948
C-4-I GDSC2 0.953 5.9512 -1.1449 18.8393
HeLa GDSC2; CTRP2 1.5554 1.9288 1.5554 23.2441
OVCA420 GDSC2 1.9157 3.7336 0.7723 4.2599
OVMIU GDSC2 2.4659 7.9442 -0.8937 12.9902
SiHa GDSC2 2.4957 10.3194 -2.0484 18.8431
SW756 GDSC2 3.0975 20.5575 -6.6721 31.1558
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Teniposide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Vincristine DMINOX3 Minor Decreased metabolism of Teniposide caused by Vincristine mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [15]
Coadministration of a Drug Treating the Disease Different from Teniposide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Moderate Accelerated clearance of Teniposide due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [16]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Teniposide caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [17]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Teniposide and Roflumilast. Asthma [CA23] [16]
Ofloxacin DM0VQN3 Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [18]
Ciprofloxacin XR DM2NLS9 Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [18]
Trovafloxacin DM6AN32 Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Trovafloxacin. Bacterial infection [1A00-1C4Z] [18]
Sparfloxacin DMB4HCT Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [18]
Gemifloxacin DMHT34O Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [18]
Norfloxacin DMIZ6W2 Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [18]
ABT-492 DMJFD2I Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [18]
Levofloxacin DMS60RB Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [18]
Lomefloxacin DMVRH9C Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [18]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Teniposide caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [19]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Teniposide caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [20]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Teniposide caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [21]
Tucatinib DMBESUA Moderate Decreased metabolism of Teniposide caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [22]
Mifepristone DMGZQEF Moderate Decreased metabolism of Teniposide caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [23]
MK-8228 DMOB58Q Moderate Decreased metabolism of Teniposide caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [24]
Aprepitant DM053KT Moderate Decreased metabolism of Teniposide caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [25]
Primidone DM0WX6I Moderate Increased metabolism of Teniposide caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Teniposide caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Cenobamate DM8KLU9 Moderate Increased metabolism of Teniposide caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Teniposide caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Phenobarbital DMXZOCG Moderate Increased metabolism of Teniposide caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Carbamazepine DMZOLBI Moderate Increased metabolism of Teniposide caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Tazemetostat DMWP1BH Moderate Increased metabolism of Teniposide caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [28]
Boceprevir DMBSHMF Moderate Decreased metabolism of Teniposide caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [29]
Telaprevir DMMRV29 Moderate Decreased metabolism of Teniposide caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [30]
Rifapentine DMCHV4I Moderate Increased metabolism of Teniposide caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [31]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Teniposide and Brentuximab vedotin. Hodgkin lymphoma [2B30] [32]
Delavirdine DM3NF5G Minor Decreased metabolism of Teniposide caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [33]
Efavirenz DMC0GSJ Moderate Increased metabolism of Teniposide caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [34]
Etravirine DMGV8QU Moderate Increased metabolism of Teniposide caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Teniposide and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [36]
Darunavir DMN3GCH Moderate Decreased metabolism of Teniposide caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Teniposide and Teriflunomide. Hyper-lipoproteinaemia [5C80] [38]
Conivaptan DM1V329 Moderate Decreased metabolism of Teniposide caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [39]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Teniposide caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [40]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Teniposide and Denosumab. Low bone mass disorder [FB83] [41]
Brigatinib DM7W94S Moderate Increased metabolism of Teniposide caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [42]
Ceritinib DMB920Z Moderate Decreased metabolism of Teniposide caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [16]
PF-06463922 DMKM7EW Moderate Increased metabolism of Teniposide caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [43]
Selpercatinib DMZR15V Moderate Decreased metabolism of Teniposide caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [44]
IPI-145 DMWA24P Moderate Decreased metabolism of Teniposide caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [45]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Teniposide caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [16]
Exjade DMHPRWG Moderate Decreased metabolism of Teniposide caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [46]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Teniposide and Thalidomide. Multiple myeloma [2A83] [47]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Teniposide and Tecfidera. Multiple sclerosis [8A40] [48]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Teniposide and Siponimod. Multiple sclerosis [8A40] [23]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Teniposide and Fingolimod. Multiple sclerosis [8A40] [49]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Teniposide and Ocrelizumab. Multiple sclerosis [8A40] [50]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Teniposide and Ozanimod. Multiple sclerosis [8A40] [16]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Teniposide caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [16]
Nilotinib DM7HXWT Moderate Decreased clearance of Teniposide due to the transporter inhibition by Nilotinib. Myeloproliferative neoplasm [2A20] [51]
Dasatinib DMJV2EK Moderate Decreased metabolism of Teniposide caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [52]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Teniposide and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [53]
Modafinil DMYILBE Minor Increased metabolism of Teniposide caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [54]
Entrectinib DMMPTLH Moderate Decreased metabolism of Teniposide caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [16]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Teniposide caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [55]
Abametapir DM2RX0I Moderate Decreased metabolism of Teniposide caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [56]
Lefamulin DME6G97 Moderate Decreased metabolism of Teniposide caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [57]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Teniposide caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [58]
Enzalutamide DMGL19D Moderate Increased metabolism of Teniposide caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [59]
Bosentan DMIOGBU Moderate Increased metabolism of Teniposide caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [60]
Gatifloxacin DMSL679 Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [18]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Teniposide and Canakinumab. Rheumatoid arthritis [FA20] [61]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Teniposide and Rilonacept. Rheumatoid arthritis [FA20] [61]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Teniposide and Golimumab. Rheumatoid arthritis [FA20] [62]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Teniposide and Leflunomide. Rheumatoid arthritis [FA20] [38]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Teniposide when combined with Anthrax vaccine. Sepsis [1G40-1G41] [63]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Teniposide caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [64]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Teniposide caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [16]
Larotrectinib DM26CQR Moderate Decreased metabolism of Teniposide caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [23]
Armodafinil DMGB035 Minor Increased metabolism of Teniposide caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [54]
LEE011 DMMX75K Moderate Decreased metabolism of Teniposide caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [65]
Fostamatinib DM6AUHV Moderate Decreased clearance of Teniposide due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [66]
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Teniposide and Azathioprine. Transplant rejection [NE84] [23]
Cinoxacin DM4EWNS Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [18]
Nalidixic acid DMRM0JV Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Nalidixic acid. Urinary tract infection [GC08] [18]
Enoxacin DMYTE6L Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Enoxacin. Urinary tract infection [GC08] [18]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Teniposide and Ganciclovir. Virus infection [1A24-1D9Z] [23]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Teniposide and Valganciclovir. Virus infection [1A24-1D9Z] [23]
⏷ Show the Full List of 82 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6843).
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7.
8 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
9 Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther. 2001 Dec;39(12):517-28.
10 Drug Interactions Flockhart Table
11 O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol. 1994 Feb;45(2):352-8.
12 Regulation of Hepatic Cholesteryl Ester Transfer Protein Expression and Reverse Cholesterol Transport by Inhibition of DNA Topoisomerase II. J Biol Chem. 2015 Jun 5;290(23):14418-29. doi: 10.1074/jbc.M115.643015. Epub 2015 Apr 25.
13 Adenovirus-mediated transfer of siRNA against basic fibroblast growth factor mRNA enhances the sensitivity of glioblastoma cells to chemotherapy. Med Oncol. 2011 Mar;28(1):24-30. doi: 10.1007/s12032-010-9445-z. Epub 2010 Feb 24.
14 Suppression of c-myc expression and c-Myc function in response to sustained DNA damage in MCF-7 breast tumor cells. Biochem Pharmacol. 2001 Sep 1;62(5):593-602. doi: 10.1016/s0006-2952(01)00699-2.
15 Product Information. Oncovin (vincristine). Lilly, Eli and Company, Indianapolis, IN.
16 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
18 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
19 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
20 Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
21 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
22 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
23 Cerner Multum, Inc. "Australian Product Information.".
24 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
25 Charasson V, Haaz MC, Robert J "Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan." Drug Metab Dispos 30 (2002): 731-733. [PMID: 12019202]
26 Baker DK, Relling MV, Pui CH, Christensen ML, Evans WE, Rodman JH "Increased teniposide clearance with concomitant anticonvulsant therapy." J Clin Oncol 10 (1992): 311-5. [PMID: 1732431]
27 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
28 Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
29 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
30 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
31 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
32 Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
33 Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, Kauffman CA, Meyer KM, Amidon GL, Stetson PL "Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test." Clin Pharmacol Ther 61 (1997): 531-43. [PMID: 9164415]
34 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
35 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
36 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
37 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
38 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
39 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
40 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
41 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
42 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
43 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
44 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
45 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
46 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
47 Figg WD, Arlen P, Gulley J, et al. "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer." Semin Oncol 28(4 Suppl 15) (2001): 62-6. [PMID: 11685731]
48 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
49 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
50 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
51 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
52 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
53 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
54 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
55 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
56 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
57 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
58 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
59 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
60 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
61 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
62 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
63 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
64 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
65 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
66 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.